AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.42
0.01 (0.35%)
▲
5d:
-1.05%
30d:
-12.11%
90d:
-32.62%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
8 traders called AKBA this week
94% bullish • 1 bearish
94% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AKBA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: AKBA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.42, which is considered slightly low relative to its 30-day fair value range of $1.38 to $1.60. The stock's valuation (Forward PE: 8.3) is in line with its historical norms (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AKBA is in a strong downtrend. Immediate support is located at $1.30, while resistance sits at $1.53.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.40 (+283.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AKBA is in a strong downtrend. Immediate support is located at $1.30, while resistance sits at $1.53.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.40 (+283.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$1.38 -
$1.60
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 283.0% below Wall St target ($5.40)
Fair Price Analysis
30-Day Fair Range
$1.38 -
$1.60
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.53
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
8.29
Wall Street Target
$5.40
(+283.0%)
Revenue Growth (YoY)
57.0%
Profit Margin
-7.1%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
8.3 vs 8.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$1.39
(-2%)
2-Year Target
$1.37
(-3%)
3-Year Target
$1.35
(-4%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$1.41
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 325.0%)
$12.79
(+807%)
Base:
(SPY PE: 8.3, Growth: 325.0%)
$4.76
(+238%)
Bear:
(PE: 7.0, Growth: 325.0%)
$4.04
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.3 to 8.7
Stabilization Target:
$1.48
(+4.9%)
PE Expansion Potential:
+4.9%
Last updated: February 02, 2026 10:28 AM ET
Data refreshes hourly during market hours. Next update: 11:28 AM
Data refreshes hourly during market hours. Next update: 11:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
